BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 25880756)

  • 1. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study.
    Jacobson MP; Pazdera L; Bhatia P; Grinnell T; Cheng H; Blum D;
    BMC Neurol; 2015 Mar; 15():46. PubMed ID: 25880756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America.
    Sperling MR; Harvey J; Grinnell T; Cheng H; Blum D;
    Epilepsia; 2015 Apr; 56(4):546-55. PubMed ID: 25689448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.
    Sperling MR; Abou-Khalil B; Harvey J; Rogin JB; Biraben A; Galimberti CA; Kowacs PA; Hong SB; Cheng H; Blum D; Nunes T; Soares-da-Silva P;
    Epilepsia; 2015 Feb; 56(2):244-53. PubMed ID: 25528898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to eslicarbazepine acetate monotherapy: A pooled analysis of 2 phase III studies.
    Sperling MR; French J; Jacobson MP; Pazdera L; Gough M; Cheng H; Grinnell T; Blum D;
    Neurology; 2016 Mar; 86(12):1095-102. PubMed ID: 26911639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy following conversion to eslicarbazepine acetate monotherapy in adults with focal seizures.
    Chung S; Sinha SR; Shah A; Stern JM; Cheng H; Jung J; Grinnell T; Blum D
    Epilepsy Res; 2019 Jul; 153():59-65. PubMed ID: 30999260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study.
    Elger C; Halász P; Maia J; Almeida L; Soares-da-Silva P;
    Epilepsia; 2009 Mar; 50(3):454-63. PubMed ID: 19243424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.
    Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P;
    Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: Two double-blind, randomized, multicenter, historical control, Phase III studies.
    Arnold S; Badalamenti V; Diaz A; Gasalla T; McShea C; Whitesides J; Fakhoury T
    Epilepsy Res; 2018 Mar; 141():73-82. PubMed ID: 29486396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of eslicarbazepine acetate monotherapy for partial-onset seizures: Experience from a multicenter, observational study.
    Toledano R; Jovel CE; Jiménez-Huete A; Bayarri PG; Campos D; Gomariz EL; Giráldez BG; García-Morales I; Falip M; Agredano PM; Palao S; Prior MJAA; Pascual MRQ; Navacerrada FJ; González FJL; Ojeda J; Sáez AA; Bermejo PE; Gil-Nagel A
    Epilepsy Behav; 2017 Aug; 73():173-179. PubMed ID: 28641170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive eslicarbazepine acetate: A pooled analysis of three phase III trials.
    Biton V; Rogin JB; Krauss G; Abou-Khalil B; Rocha JF; Moreira J; Gama H; Trinka E; Elger CE; Cheng H; Grinnell T; Blum D;
    Epilepsy Behav; 2017 Jul; 72():127-134. PubMed ID: 28575761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eslicarbazepine Acetate Monotherapy: A Review in Partial-Onset Seizures.
    Shirley M; Dhillon S
    Drugs; 2016 Apr; 76(6):707-17. PubMed ID: 27055527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies.
    Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P
    CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy.
    Sunkaraneni S; Passarell JA; Ludwig EA; Fiedler-Kelly J; Pitner JK; Grinnell TA; Blum D
    Clin Pharmacol; 2017; 9():65-72. PubMed ID: 28721105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in patients treated with eslicarbazepine acetate monotherapy: Pooled analysis from two registered clinical trials.
    Cramer JA; Rajagopalan K; Anastassopoulos KP; Blum D;
    Epilepsy Behav; 2019 Mar; 92():31-35. PubMed ID: 30611005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.
    Ben-Menachem E; Gabbai AA; Hufnagel A; Maia J; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2010 May; 89(2-3):278-85. PubMed ID: 20299189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures.
    Sunkaraneni S; Ludwig EA; Passarell JA; Blum D; Grinnell T; Fiedler-Kelly J
    J Clin Pharmacol; 2018 Jul; 58(7):927-938. PubMed ID: 29528499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase-III clinical trial.
    Kirkham F; Auvin S; Moreira J; Gama H; Falcão AC; Rocha JF; Soares-da-Silva P
    Epilepsy Behav; 2020 Apr; 105():106962. PubMed ID: 32151803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study.
    Hufnagel A; Ben-Menachem E; Gabbai AA; Falcão A; Almeida L; Soares-da-Silva P
    Epilepsy Res; 2013 Feb; 103(2-3):262-9. PubMed ID: 22871333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies.
    Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS
    Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.
    Trinka E; Ben-Menachem E; Kowacs PA; Elger C; Keller B; Löffler K; Rocha JF; Soares-da-Silva P
    Epilepsia; 2018 Feb; 59(2):479-491. PubMed ID: 29369348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.